Investigación / Grupos de investigación

Grupo  2

Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Publicaciones (884)

  • Calles A; Calvo E; Santamaría Nuñez G; Costanzo F; Guillén MJ; Martinez Diez M; Gupta A; Cuevas C; Egly JM; Aviles P.

    Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.

    MOLECULAR CANCER THERAPEUTICS. 2025; 24(6): 828-839 Nº de citas: 1 [doi:10.1158/1535-7163.MCT-24-0050]

  • Martín, AJM; Castet, F; Alsar, JS; Adeva, J; Peinado, P; Graña, B; Díaz, IA; Rodríguez-Alonso, RM; de Mena, ML; Vera, R; de Mena, IR; Aguilar, S; Vega, S; Morán, LO; Macarulla, T.

    MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry

    Esmo Gastrointestinal Oncology. 2025; 8: 100187-100187 Nº de citas: 1 [doi:10.1016/j.esmogo.2025.100187]

  • Pelegrín-Mateo, FJ; Zambrano, CB; Vázquez, EB; Escobar, IG; Martín, AM.

    Cancer genetic profile and risk of thrombosis

    EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2025; 136: 19-26 [doi:10.1016/j.ejim.2025.04.004]

  • Shinn, E; Zahrieh, D; DeMichele, A; Zdenkowski, N; Lemieux, J; Mao, J; Bjelic-Radisic, V; Naughton, MJ; Pfeiler, G; Gelmon, K; Balko, JM; Egle, D; Zoppoli, G; Traina, T; Jimenez, MM; Novoa, SA; Haddad, T; Chan, A; Ring, A; Wolff, A; Symmans, WF; Lorenzo, JP; Sabanathan, D; Burstein, HJ; Nowecki, ZI; Pristauz-Telsnigg, G; Brufsky, A; Bellet-Ezquerra, M; Foukakis, T; Novik, Y; Rubovszky, G; Singer, CF; Muehlbacher, K; Metzger, O; Goulioti, T; Law, E; Partridge, AH; Carey, LA; Zoroufy, A; Hlauschek, D; Fesl, C; Mayer, EL; Gnant, M.

    Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer

    BREAST CANCER RESEARCH AND TREATMENT. 2025; 211(2): 385-397 [doi:10.1007/s10549-025-07653-2]

  • Yu EY; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PC; Piulats JM; Berry W; Emmenegger U; Mourey L; Joshua AM; Mar N; Appleman LJ; Conter HJ; Gravis G; Li XT; Schloss C; Poehlein C; de Bono JS.

    Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.

    European Urology Oncology. 2025; 8(3): 641-651 Nº de citas: 1 [doi:10.1016/j.euo.2024.05.013]

  • Besse, B; Goto, K; Wang, YS; Lee, SH; Marmarelis, ME; Ohe, Y; Bernabe, R; Kim, DW; Lee, JS; Cousin, S; Ichihara, E; Li, YS; Paz-Ares, L; Ono, A; Sanborn, RE; Watanabe, N; de Miguel, MJ; Helissey, C; Shu, CA; Spira, AI; Tomasini, P; Yang, JCH; Zhang, YP; Felip, E; Griesinger, F; Waqar, SN; Calles, A; Neal, JW; Baik, CS; Jaenne, PA; Shreeve, SM; Curtin, JC; Patel, B; Gormley, M; Lyu, X; Chen, J; Chu, PL; Mahoney, J; Trani, L; Bauml, JM; Thayu, M; Knoblauch, RE; Cho, BC.

    Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A

    JOURNAL OF THORACIC ONCOLOGY. 2025; 20(5): 651-664 Nº de citas: 8 [doi:10.1016/j.jtho.2024.12.029]

  • Fasching, PA; Slamon, D; Nowecki, Z; Kukielka-Budny, B; Stroyakovskiy, D; Yardley, DA; Huang, CS; Chan, A; Chia, S; Martín, M; Rugo, HS; Loi, S; Hurvitz, S; Untch, M; Afenjar, K; Fresco, R; Danyliv, A; Ferrusi, I; Li, Z; Hortobagyi, G.

    Health-Related Quality of Life in Patients with HR+/HER2-Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

    CLINICAL CANCER RESEARCH. 2025; 31(9): 1625-1635 Nº de citas: 1 [doi:10.1158/1078-0432.CCR-24-1724]

  • Varela, M; Teixidó, C; Alvarez-Fernández, C; Arasanz, H; Peralta, S; Lázaro, M; Calvo, V; Alvarez, R; Baena, J; Valdivia, J; Arriola, E; Bernabé, R; Isla, D; Camacho, C; Massutí, B; Blasco, A; García, T; Cobo, M; Campayo, M; Hijazo-Pechero, S; Callejo, A; Dominguez, M; Nadal, E.

    Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study

    Translational Lung Cancer Research. 2025; 14(4): [doi:10.21037/tlcr-2024-1146]

  • Vinuela-Beneitez, MC; Pérez, CI; Morán, LO; Escobar, IG; Lavín, DC; Balanyà, RPI; Adrián, SG; Campos, MC; López, GB; Crespo, JAS; de Mena, ML; Altozano, JP; Díaz, EG; Peces, JT; Rivas, PO; Morales, MJO; Rubio, VEC; Pedroche, CD; Sueiro, MR; Gonçalves, F; Sánchez-Cánovas, M; Ruiz, MA; Muñoz-Langa, J; Segura, PP; de Castro, EM; Carmona-Bayonas, A; Jiménez-Fonseca, P; Martín, AJM.

    External validation of a prediction model for bleeding events in anticoagulated cancer patients with venous thromboembolism (PredictAI)

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-03890-5]

  • Valladares-Ayerbes, M; Toledano-Fonseca, M; Graña, B; Jimenez-Fonseca, P; Pulido-Cortijo, G; Gil, S; Sastre, J; Salud, A; Rivera, F; Salgado, M; García-Alfonso, P; López, RL; Guillén-Ponce, C; Rodríguez-Ariza, A; Vieitez, JM; Díaz-Rubio, E; Aranda, E; Spanish Cooperat Grp Treatment Digest Tumours TTD.

    Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer

    BMC CANCER. 2025; 25(1): [doi:10.1186/s12885-025-14098-9]

  • García-Saenz, JA; Spera, G; Pollán, M; Bermejo, B; Ruiz-Borrego, M; Chan, A; Martín, M; Guerrero-Zotano, A; Calvo, L; Rodríguez-Lescure, A; Marín, M; Chap, L; Crown, J; Pienkowski, T; Bee, V; Casas, M; Polonio, O; Bezares, S; Slamon, D.

    Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

    INTERNATIONAL JOURNAL OF CANCER. 2025; 157(4): 709-721 [doi:10.1002/ijc.35432]

  • Capdevila, J; Pubul, V; Anido, U; Walter, T; Molina-Cerrillo, J; Alonso-Gordoa, T; Garcia-Carbonero, R; San-Roman-Gil, M; Llana, B; Jimenez-Fonseca, P; Viñuales, MB; Ansquer, C; Baudin, E; Lepage, C; del Olmo-García, M; Ruffinelli, JC; Beron, A; Haissaguerre, M; Deshayes, E; Taïeb, D; Baldari, S; Sansovini, M; Cingarlini, S; Filice, A; Panzuto, F; Alvarez-Alvarez, R; Lousberg, L; Nana, FA; Hernando, J; García-Alvarez, A; García-Burillo, A; Villacampa, G; Vandamme, T; Fazio, N; Durand, A.

    A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

    BMC CANCER. 2025; 25(1): [doi:10.1186/s12885-025-13941-3]

  • Galsky, MD; Kockx, M; Roels, J; Van Elzen, R; Guan, XN; Yuen, K; Rishipathak, D; Anker, JF; Gnjatic, S; Izadmehr, S; Sanjabi, S; Johnston, RJ; Peterson, M; Koeppen, H; David, JM; Gupta, S; Bamias, A; Arranz, JA; Kikuchi, E; De Santis, M; Davis, ID; Williams, P; Bernhard, S; Mellman, I; Grande, E; Banchereau, R; Mariathasan, S.

    Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer

    Cancer Immunology Research. 2025; 13(4): 476-486 Nº de citas: 2 [doi:10.1158/2326-6066.CIR-24-0649]

  • Alonso-Gonzalo, L; Oblitas, CM; Cebollero-Presmanes, M; Vieru, CM; García-Leoni, ME.

    Hepatoid adenocarcinoma of the lung: a rare case report

    Galicia Clinica. 2025; 86(2): 27-29 [doi:10.22546/86/2/1272]

  • Hahnen, E; Hauke, J; Gelmon, K; Marmé, F; Ernst, C; Martin, M; Untch, M; Bonnefoi, H; Knudsen, E; Im, SA; DeMichele, A; Van't Veer, L; Kim, SB; Bear, H; McCarthy, N; Rhiem, K; Turner, N; Witkiewicz, A; Rojo, F; Filipits, M; Martin, LA; Fasching, PA; Schem, C; Becker, K; García-Sáenz, JA; Kelly, CM; Reimer, T; Toi, M; Rugo, HS; Denkert, C; Gnant, M; Makris, A; Liu, Y; Valota, O; Felder, B; Weber, K; Nekljudova, V; Loibl, S.

    BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor plus /Human Epidermal Growth Factor Receptor 2-Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis

    Jco Precision Oncology. 2025; 9: [doi:10.1200/PO-24-00742]

  • Lopez-Tarruella, S; Pollán, M; Carrasco, E; Andrés, R; Martín, M; Servitja, S; Bermejo, B; Antón, A; Guerrero-Zotano, A; Muñoz, M; Fernández, L; del Prado, PM; Alvarez, I; Calvo, L; Rodríguez-Lescure, A; Marín, M; Ruiz-Borrego, M; Herranz, J; Polonio, O; Adrover, E; Moreno, D.

    Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

    ONCOLOGIST. 2025; 30(4): [doi:10.1093/oncolo/oyaf040]

  • Koshkin VS; Danchaivijitr P; Bae WK; Semenov A; Ozyilkan O; Su YL; Arranz Arija JA; Tsujihata M; Bögemann M; Hendriks MP; Delgado SN; Rosenbaum E; Lopez KA; Bavle A; Liu CC; Imai K; Furka A.

    Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.

    EUROPEAN UROLOGY. 2025; 87(4): 390-395 Nº de citas: 2 [doi:10.1016/j.eururo.2024.11.012]

  • Giannatempo, P; Machiels, JP; Sassa, N; Arranz, JA; Fujii, Y; Su, WP; Keam, B; Culine, S; Shen, YC; Langa, JM; Sarid, D; Aarts, M; Calabro, F; Rosenbaum, E; Moreno, BH; Bavle, A; Xu, JZ; Rha, SY.

    Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials

    CLINICAL GENITOURINARY CANCER. 2025; 23(2): [doi:10.1016/j.clgc.2024.102273]